Home > Boards > US Listed > Biotechs > Anavex Life Sciences Corp (AVXL)

The one thing I heard in the presentation

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (2) | Next 10 | Previous | Next
Steady_T Member Profile
Member Level 
Followed By 129
Posts 16,070
Boards Moderated 2
Alias Born 12/09/04
160x600 placeholder
Anavex Life Sciences to Present at the Dawson James Securities 6th Annual Conference GlobeNewswire Inc. - 10/15/2021 7:00:00 AM
Anavex Life Sciences Reports Data Review by the Independent Data Safety Monitoring Board for its Phase 2b/3 Clinical Trial of ANAVEX®2-73 in Patients with Alzheimer’s Disease GlobeNewswire Inc. - 10/13/2021 7:00:00 AM
Cassava down after phase 3 simufilam announcement; other Alzheimer's names follow Seeking Alpha - 10/6/2021 12:51:22 PM
CEO Presenting on the Emerging Growth Conference on September 29  Register Now InvestorsHub NewsWire - 9/28/2021 8:00:00 AM
Anavex Life Sciences Announces Participation at 5th Pharma Pricing, Reimbursement & Market Access 2021 GlobeNewswire Inc. - 9/27/2021 9:30:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 9/27/2021 8:11:01 AM
Anavex Life Sciences Announces Uplisting to the NASDAQ Global Select Market® GlobeNewswire Inc. - 9/27/2021 7:00:00 AM
Automatic Shelf Registration Statement of Securities of Well-known Seasoned Issuers (s-3asr) Edgar (US Regulatory) - 9/24/2021 5:05:26 PM
Anavex Life Sciences to Present at the 2021 Cantor Virtual Global Healthcare Conference GlobeNewswire Inc. - 9/20/2021 7:00:00 AM
CEO Presenting on the Emerging Growth Conference Today!  Register Now InvestorsHub NewsWire - 9/15/2021 7:00:00 AM
Anavex Life Sciences to Present at the H.C. Wainwright 23rd Annual Global Investment Conference GlobeNewswire Inc. - 9/9/2021 7:00:00 AM
CEO Presenting on the Emerging Growth Conference Today.  Register Now InvestorsHub NewsWire - 9/1/2021 7:00:00 AM
Anavex Life Sciences Announces Publication of Foundational Data for ANAVEX®2-73 (blarcamesine) in Fragile X Syndrome (Autism) GlobeNewswire Inc. - 8/26/2021 7:00:00 AM
Quarterly Report (10-q) Edgar (US Regulatory) - 8/12/2021 5:13:54 PM
Anavex Life Sciences Provides Business Update and Reports Fiscal 2021 Third Quarter Financial Results GlobeNewswire Inc. - 8/12/2021 7:00:00 AM
Anavex Life Sciences to Announce Fiscal 2021 Third Quarter Financial Results on Thursday, August 12, 2021 GlobeNewswire Inc. - 8/5/2021 7:00:00 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 8/4/2021 5:41:46 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 8/4/2021 5:39:35 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 8/4/2021 5:36:53 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 8/4/2021 5:31:15 PM
CEO Presenting on the Emerging Growth Conference Today.  Register Now InvestorsHub NewsWire - 8/4/2021 7:00:00 AM
Anavex Life Sciences to Participate in the BTIG Virtual Biotechnology Conference 2021 GlobeNewswire Inc. - 8/4/2021 7:00:00 AM
Cassava Sciences drags rivals lower amid concerns over its Alzheimer’s drug Seeking Alpha - 7/30/2021 9:03:44 AM
Anavex Life Sciences rises on positive data for Alzheimer’s therapy in mouse study Seeking Alpha - 7/29/2021 7:46:45 AM
Anavex Life Sciences Announces ANAVEX®2-73 (Blarcamesine) Significantly Prevented Aβ (Abeta)-induced Cognitive Deficits with Confirmed Significant Biomarker-response in Animal Model of Alzheimer’s Disease GlobeNewswire Inc. - 7/29/2021 7:00:00 AM
Steady_T Member Level  Thursday, 04/15/21 10:23:48 AM
Re: LBSR TO DA MOON post# 307118
Post # of 333980 
The one thing I heard in the presentation that caught my attention was when Missling said that 2-73 works even further upstream than we thought it did.

That comment was with the slide about chromatin.

The further upstream in the disease processes that 2-73 intervenes, the wider the applicability of the drug. So it seems to me that ultimately 2-73 will be utilized in more indications than are presently being targeted. Probably indications that have not even been considered at this point.

Of course that does lead to 2-73 as a general tonic for aging. Which may be the largest market of all.

I also found interesting that slide that showed the dosages being stepped up in 10 mg increments to the ultimate targeted dose. I was not previously aware of that part of the protocol.



The American Republic will endure until the day Congress discovers that it can bribe the public with its own money.
Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (2) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist
Consent Preferences